These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

99 related articles for article (PubMed ID: 30853287)

  • 21. The efficacy and safety of direct acting antiviral treatment and clinical significance of drug-drug interactions in elderly patients with chronic hepatitis C virus infection.
    Vermehren J; Peiffer KH; Welsch C; Grammatikos G; Welker MW; Weiler N; Zeuzem S; Welzel TM; Sarrazin C
    Aliment Pharmacol Ther; 2016 Oct; 44(8):856-65. PubMed ID: 27549000
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Adding ribavirin to newer DAA regimens does not affect SVR rates in HCV genotype 1 infected persons: results from ERCHIVES.
    Butt AA; Yan P; Marks K; Shaikh OS; Sherman KE;
    Aliment Pharmacol Ther; 2016 Oct; 44(7):728-37. PubMed ID: 27459341
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dual treatment with sofosbuvir plus ribavirin is as effective as triple therapy with pegylated interferon plus sofosbuvir plus ribavirin in predominant genotype 3 patients with chronic hepatitis C.
    Satsangi S; Mehta M; Duseja A; Taneja S; Dhiman RK; Chawla Y
    J Gastroenterol Hepatol; 2017 Apr; 32(4):859-863. PubMed ID: 27624314
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Experience in real clinical practice with new direct acting antivirals in chronic hepatitis C.
    Jiménez-Macías FM; Cabanillas-Casafranca M; Maraver-Zamora M; Romero-Herrera G; García-García F; Correia-Varela-Almeida A; Cabello-Fernández A; Ramos-Lora M
    Med Clin (Barc); 2017 Nov; 149(9):375-382. PubMed ID: 28416232
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Treatment of HCV infection in liver transplant recipients with ledipasvir and sofosbuvir without ribavirin.
    Pillai AA; Maheshwari R; Vora R; Norvell JP; Ford R; Parekh S; Cheng N; Patel A; Young N; Spivey JR; Mgbemena O; Wedd JP
    Aliment Pharmacol Ther; 2017 Jun; 45(11):1427-1432. PubMed ID: 28382751
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Efficacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis C.
    Fernández I; Muñoz-Gómez R; Pascasio JM; Baliellas C; Polanco N; Esforzado N; Arias A; Prieto M; Castells L; Cuervas-Mons V; Hernández O; Crespo J; Calleja JL; Forns X; Londoño MC
    J Hepatol; 2017 Apr; 66(4):718-723. PubMed ID: 28039098
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Real-world results of direct-acting antivirals use for the treatment of chronic hepatitis C in old patients.
    El Kassas M; El Sheemy R; Alboraie M; El Badry M; Wifi MN; Youssef N; Ezzat S; Tahoon M; Abdelsalam L; Abdelhakam SM; Ali-Eldin Z
    Eur Geriatr Med; 2019 Apr; 10(2):295-302. PubMed ID: 34652758
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sofosbuvir-based therapy for patients with chronic hepatitis C: Early experience of its efficacy and safety in Korea.
    Cho Y; Cho EJ; Lee JH; Yu SJ; Yoon JH; Kim YJ
    Clin Mol Hepatol; 2015 Dec; 21(4):358-64. PubMed ID: 26770924
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The elderly and direct antiviral agents: Constraint or challenge?
    Fabrizio C; Saracino A; Scudeller L; Milano E; Dell'Acqua R; Bruno G; Lo Caputo S; Monno L; Milella M; Angarano G
    Dig Liver Dis; 2017 Sep; 49(9):1036-1042. PubMed ID: 28651903
    [TBL] [Abstract][Full Text] [Related]  

  • 30. All-oral direct-acting antiviral therapy in HCV-advanced liver disease is effective in real-world practice: observations through HCV-TARGET database.
    Reddy KR; Lim JK; Kuo A; Di Bisceglie AM; Galati JS; Morelli G; Everson GT; Kwo PY; Brown RS; Sulkowski MS; Akuschevich L; Lok AS; Pockros PJ; Vainorius M; Terrault NA; Nelson DR; Fried MW; Manns MP;
    Aliment Pharmacol Ther; 2017 Jan; 45(1):115-126. PubMed ID: 27790729
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients.
    Pol S; Bourliere M; Lucier S; Hezode C; Dorival C; Larrey D; Bronowicki JP; Ledinghen VD; Zoulim F; Tran A; Metivier S; Zarski JP; Samuel D; Guyader D; Marcellin P; Minello A; Alric L; Thabut D; Chazouilleres O; Riachi G; Bourcier V; Mathurin P; Loustaud-Ratti V; D'Alteroche L; Fouchard-Hubert I; Habersetzer F; Causse X; Geist C; Rosa I; Gournay J; Saillard E; Billaud E; Petrov-Sanchez V; Diallo A; Fontaine H; Carrat F;
    J Hepatol; 2017 Jan; 66(1):39-47. PubMed ID: 27622858
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness and safety of sofosbuvir plus ribavirin for the treatment of HCV genotype 2 infection: results of the real-world, clinical practice HCV-TARGET study.
    Welzel TM; Nelson DR; Morelli G; Di Bisceglie A; Reddy RK; Kuo A; Lim JK; Darling J; Pockros P; Galati JS; Frazier LM; Alqahtani S; Sulkowski MS; Vainorius M; Akushevich L; Fried MW; Zeuzem S;
    Gut; 2017 Oct; 66(10):1844-1852. PubMed ID: 27418632
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adverse events associated with ribavirin in sofosbuvir-based therapies for patients with chronic hepatitis C: A community practice experience.
    Tong MJ; Chang PW; Huynh TT; Rosinski AA; Tong LT
    J Dig Dis; 2016 Feb; 17(2):113-21. PubMed ID: 26749171
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Identification of the Best Direct-Acting Antiviral Regimen for Patients With Hepatitis C Virus Genotype 3 Infection: A Systematic Review and Network Meta-analysis.
    Berden FA; Aaldering BR; Groenewoud H; IntHout J; Kievit W; Drenth JP
    Clin Gastroenterol Hepatol; 2017 Mar; 15(3):349-359. PubMed ID: 27840182
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of 6 or 8 weeks of simeprevir, daclatasvir, sofosbuvir for HCV genotype 1 infection.
    Sulkowski MS; Feld JJ; Lawitz E; Felizarta F; Corregidor AM; Khalid O; Ghalib R; Smith WB; Van Eygen V; Luo D; Vijgen L; Gamil M; Kakuda TN; Ouwerkerk-Mahadevan S; Van Remoortere P; Beumont M
    J Viral Hepat; 2018 Jun; 25(6):631-639. PubMed ID: 29274193
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and Safety of Direct Acting Antivirals in Kidney Transplant Recipients with Chronic Hepatitis C Virus Infection.
    Lin MV; Sise ME; Pavlakis M; Amundsen BM; Chute D; Rutherford AE; Chung RT; Curry MP; Hanifi JM; Gabardi S; Chandraker A; Heher EC; Elias N; Riella LV
    PLoS One; 2016; 11(7):e0158431. PubMed ID: 27415632
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ledipasvir-sofosbuvir: interferon-/ribavirin-free regimen for chronic hepatitis C virus infection.
    Smith MA; Chan J; Mohammad RA
    Ann Pharmacother; 2015 Mar; 49(3):343-50. PubMed ID: 25515863
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Week 4 response predicts sustained virological response to all-oral direct-acting antiviral-based therapy in cirrhotic patients with hepatitis C virus genotype 3 infection.
    Pineda JA; Morano-Amado LE; Granados R; Macías J; Téllez F; García-Deltoro M; Ríos MJ; Collado A; Delgado-Fernández M; Suárez-Santamaría M; Serrano M; Miralles-Álvarez C; Neukam K; ;
    Clin Microbiol Infect; 2017 Jun; 23(6):409.e5-409.e8. PubMed ID: 28137633
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low-Dose Sofosbuvir Is Safe and Effective in Treating Chronic Hepatitis C in Patients with Severe Renal Impairment or End-Stage Renal Disease.
    Taneja S; Duseja A; De A; Mehta M; Ramachandran R; Kumar V; Kohli HS; Gupta KL; Dhiman RK; Chawla Y
    Dig Dis Sci; 2018 May; 63(5):1334-1340. PubMed ID: 29484572
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Treatment of HCV genotype 2 with sofosbuvir and ribavirin results in lower sustained virological response rates in real life than expected from clinical trials.
    Tacke F; Günther R; Buggisch P; Klinker H; Schober A; John C; Lutz T; Pfeiffer-Vornkahl H; Niederau C; Cornberg M; Sarrazin C; Mauss S
    Liver Int; 2017 Feb; 37(2):205-211. PubMed ID: 27428297
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.